Activins and inhibins in endocrine and other tumors

Endocrine Reviews

Volumn 22, Issue 6, 2001, Pages 836-858

  Risbridger, Gail P ^a,c   Schmitt, Jacqueline F ^a   Robertson, David M ^b  

^a MONASH UNIVERSITY   (Australia)

^b HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^c MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN RECEPTOR; INHIBIN; INHIBIN A; MYELOPID; TRANSFORMING GROWTH FACTOR BETA;

ADRENAL TUMOR; ANIMAL EXPERIMENT; ANIMAL MODEL; BREAST TUMOR; CARCINOGENESIS; CONTROLLED STUDY; ENDOCRINE TUMOR; ENDOMETRIUM TUMOR; HORMONE RECEPTOR INTERACTION; HYPOPHYSIS TUMOR; KIDNEY TUMOR; LIVER TUMOR; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOUSE; NONHUMAN; OVARY TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROSTATE TUMOR; REVIEW; SIGNAL TRANSDUCTION; TESTIS TUMOR; TRANSGENIC MOUSE; TUMOR PROMOTION;

EID: 0035719848     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.22.6.0450     Document Type: Review

References (279)

1. TGF-β signal transduction
2. Specificity, diversity, and regulation in TGF-β superfamily signaling
3. The inhibin/activin family of hormones and growth factors
4. Activins, inhibins, and follistatins: Further thoughts on a growing family of regulators
5. Cloning of a new member of the TGF-β superfamily: A putative new activin βC chain
6. Molecular cloning and functional analysis of a new activin β subunit: A dorsal mesoderm-inducing activity in Xenopus
7. Structure, chromosomal localization, and expression analysis of the mouse inhibin/activin βC (Inhbc) gene
8. Molecular cloning of the mouse activin βE subunit gene
9. Genes coding for mouse activin βC and βE are closely linked and exhibit a liver-specific expression pattern in adult tissues
10. Localization of activin βA, βA and βC subunits in human prostate and evidence for formation of new activin heterodimers of βC subunit
11. Activin βC and βE genes are not essential for mouse liver growth, differentiation, and regeneration
12. Purification and characterization of high molecular weight forms of inhibin from bovine follicular fluid
13. Isolation of inhibin α subunit precursor proteins from bovine follicular fluid
14. The radioimmunoassay of bovine and human follicular fluid and serum inhibin
15. Characterization and determination of the biological activities of noncleavable high molecular weight forms of inhibin A and activin A
16. Source of circulating levels of inhibin A, pro αC-containing inhibins and activin A in early pregnancy
17. Measurement of dimeric inhibin B throughout the human menstrual cycle
18. Quantification of inhibin pro-αC-containing forms in human serum by a new ultrasensitive two-site enzyme-linked immunosorbent assay
19. Changes in peripheral serum levels of total activin A during the human menstrual cycle and pregnancy
20. Combined inhibin and CA125 assays in the detection of ovarian cancer
21. Activins and the receptor serine kinase superfamily
22. TGF-β signaling from cell membrane to nucleus through SMAD proteins
23. Signaling of transforming growth factor-β family members through Smad proteins
24. Roles of pathway-specific and inhibitory Smads in activin receptor signaling
25. Smads: Transcriptional activators of TGF-β responses
26. SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor
27. The Smad pathway
28. Smads as transcriptional co-modulators
29. Smad4 and FAST-1 in the assembly of activin-responsive factor
30. A transcriptional partner for MAD proteins in TGF-β signalling
31. Smad2 and Smad3 positively and negatively regulate TGF β-dependent transcription through the forkhead DNA-binding protein FAST2
32. Signaling inputs converge on nuclear effectors in TGF-β signaling
33. Identification of high affinity binding sites for inhibin on ovine pituitary cells in culture
34. Is the action of inhibin mediated via a unique receptor?
35. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism
36. Inhibin interferes with activin signaling at the level of the activin receptor complex in Chinese hamster ovary cells
37. Betaglycan binds inhibin and can mediate functional antagonism of activin signalling
38. Structure and expression of a membrane component of the inhibin receptor system
39. In search of binding-identification of inhibin receptors
40. Activin signal transduction pathways
41. Follistatin: A multifunctional regulatory protein
42. Roles of inhibins, activins, and follistatin in the female reproductive system
43. Direct binding of follistatin to a complex of bone-morphogenetic protein and its receptor inhibits ventral and epidermal cell fates in early Xenopus embryo
44. Identification and characterization of a novel follistatin-like protein (FSLP) as a binding protein for the TGF-β family
45. Identification and characterization of binding proteins for inhibin and activin in human serum and follicular fluids
46. Recombinant human activin-A promotes proliferation of human luteinized preovulatory granulosa cells in vitro
47. Modulation of granulosa cell deoxyribonucleic acid synthesis and differentiation by activin
48. Activin: An endocrine or paracrine agent?
49. α-Inhibin is a tumour-suppressor gene with gonadal specificity in mice
50. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis
51. Development of cancer cachexia-like syndrome and adrenal tumors in inhibin-deficient mice
52. Activin signaling through activin receptor type II causes the cachexia-like symptoms in inhibin-deficient mice
53. Multiple actions of recombinant activin-A in vivo
54. Follistatin is a modulator of gonadal tumor progression and the activin-induced wasting syndrome in inhibin-deficient mice
55. Characterization of gonadal sex cord-stromal tumor cell lines from inhibin-α and p53-deficient mice: The role of activin as an autocrine growth factor
56. Transgenic models to study gonadotropin function: The role of follicle-stimulating hormone in gonadal growth and tumorigenesis
57. Male sterility in transgenic mice expressing activin βA subunit gene in testis
58. Transgenic models to study the roles of inhibins and activins in reproduction, oncogenesis, and development
59. Gonadotropins are essential modifier factors for gonadal tumor development in inhibindeficient mice
60. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors
61. Gonadal tumorigenesis in transgenic mice bearing the mouse inhibin α-subunit promoter/simian virus T-antigen fusion gene: Characterization of ovarian tumors and establishment of gonadotropin-responsive granulosa cell lines
62. Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene: Evidence for negative autoregulation of the inhibin α-subunit gene
63. Suppression of gonadotropins inhibits gonadal tumorigenesis in mice transgenic for the mouse inhibin α-subunit promoter/simian virus 40 T-antigen fusion gene
64. Long-term testosterone treatment prevents gonadal and adrenal tumorigenesis of mice transgenic for the mouse inhibin-α subunit promoter/simian virus 40 T-antigen fusion gene
65. The mouse inhibin α-subunit promoter directs SV40 T-antigen to Leydig cells in transgenic mice
66. Role of androgens in testicular tumor development in inhibin-deficient mice
67. Synergistic effects of inhibins and Mullerian-inhibiting substance on testicular tumorigenesis
68. Inhibin and p27 interact to regulate gonadal tumorigenesis
69. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1
70. Tumor suppressor activity of the TGF-β pathway in human cancers
71. Overexpression of activin-βA subunit mRNA is associated with decreased activin type II receptor mRNA levels in the testes of α-inhibin deficient mice
72. Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues
73. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma
74. N-myc down-regulates activin A
75. Loss of the expression and localization of inhibin α-subunit in high grade prostate cancer
76. Mapping of genes for inhibin subunits α, βA, and βB on human and mouse chromosomes and studies of jsd mice
77. Chromosomal localization of three human genes encoding members of the TGF-β superfamily of type I serine/threonine kinase receptors
78. Identification of allelic losses in benign, borderline, and invasive epithelial ovarian tumors and correlation with clinical outcome
79. Loss of heterozygosity at the α-inhibin locus on chromosome 2q is not a feature of human granulosa cell tumors
80. Identification of genetic markers for prostatic cancer progression
81. A genome screen of multiplex sibships with prostate cancer
82. Is potential to produce inhibins related to prognosis in ovarian granulosa cell tumors?
83. Assessment of inhibin and p53 in granulosa cell tumors of the ovary
84. Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer
85. Assignment of ACVR2 and ACVR2B the human activin receptor type II and IIB genes to chromosome bands 2q22.2→q23.3 and 3p22 and the human follistatin gene (FST) to chromosome 5q11.2 by FISH
86. Genomic organization and mapping of the human activin receptor type IIB (hActR-IIB) gene
87. Homozygous deletion map at 18q21.1 in pancreatic cancer
88. Identification of Smad2, a human Mad-related protein in the transforming growth factor β signaling pathway
89. Assignment1 of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization
90. Genetic aberrations in hypodiploid breast cancer: Frequent loss of chromosome 4 and amplification of cyclin D1 oncogene
91. Patterns of chromosomal imbalances in invasive breast cancer
92. Extensive ductal carcinoma in situ with small foci of invasive ductal carcinoma: Evidence of genetic resemblance by CGH
93. Comparative allelotyping of the short arm of human chromosome 3 in epithelial tumors of four different types
94. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer
95. Detailed genetic and physical mapping of tumor suppressor loci on chromosome 3p in ovarian cancer
96. Chromosome alterations and E-cadherin gene mutations in human lobular breast cancer
97. Genetic alterations in ERBB2-amplified breast carcinomas
98. Phyllodes tumors of the breast analyzed by comparative genomic hybridization and association of increased 1q copy number with stromal overgrowth and recurrence
99. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH): Correlation with histoprognostic variables and c-erbB-2 immunoexpression
100. Loss of heterozygosity at 3p24-p25 as a prognostic factor in breast cancer
101. Genetic abnormalities in mammary ductal intraepithelial neoplasia-flat type ("clinging ductal carcinoma in situ"): A simulator of normal mammary epithelium
102. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: Implications for tumorigenesis
103. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene
104. Detailed deletion mapping of chromosome arm 3p in breast cancers: A 2-cM region on 3p14.3-21.1 and a 5-cM region on 3p24.3-25.1 commonly deleted in tumors
105. Accumulation of chromosomal imbalances from intraductal proliferative lesions to adjacent in situ and invasive ductal breast cancer
106. Allelotype of pancreatic adenocarcinoma using xenograft enrichment
107. Genetic alterations on 3p, 11q13, and 18q in nonfamilial and MEN 1-associated pancreatic endocrine tumors
108. Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas
109. Mutations of the DPC4/Smad4 gene in neuroendocrine pancreatic tumors
110. Genetic progression and divergence in pancreatic carcinoma
111. Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH)
112. Loss of chromosome 18q is an early event in pancreatic ductal tumorigenesis
113. Mad-related genes in the human
114. Analysis of genomic alterations in sporadic adrenocortical lesions: Gain of chromosome 17 is an early event in adrenocortical tumorigenesis
115. Genetic analysis of 53 lymph node-negative breast carcinomas by CGH and relation to clinical, pathological, morphometric, and DNA cytometric prognostic factors
116. Genetic changes in breast cancer detected by comparative genomic hybridisation
117. Differential chromosome allelic imbalance in the progression of human prostate cancer
118. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations
119. Widespread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast: Comparative genomic hybridization study of pure high-grade DCIS
120. Allelotype of pancreatic acinar cell carcinoma
121. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping
122. Genetic alteration mapping on chromosome 7 in primary breast cancer
123. Genetic and chromosomal alterations in prostatic intraepithelial neoplasia and carcinoma detected by fluorescence in situ hybridization
124. Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: Tumors that recur in time display an intermediate genetic status between non-persistent and metastatic tumors
125. Interphase cytogenetics of prostatic tumor progression: Specific chromosomal abnormalities are involved in metastasis to the bone
126. Frequent allelic loss at 7p14-15 associated with aggressive histologic types of breast cancer
127. Comprehensive allelotyping of human hepatocellular carcinoma
128. Loss of heterozygosity and tumor suppressor activity of Bin1 in prostate carcinoma
129. Molecular genetic changes in human male germ cell tumors
130. Distinct chromosomal imbalances in uterine serous and endometrioid carcinomas
131. Molecular abnormalities associated with secretory carcinomas of the breast
132. A novel pancreatic endocrine tumor suppressor gene locus on chromosome 3p with clinical prognostic implications
133. Chromosome 3p24-26 and 3p22-12 loss in human prostatic adenocarcinoma
134. Chromosome alterations in breast carcinomas: Frequent involvement of DNA losses including chromosomes 4q and 21q
135. Evidence for microsatellite instability In bilateral breast carcinomas
136. Genetic pattern of prostate cancer progression
137. Comparative genomic hybridization reveals DNA copy number gains to frequently occur in human prostate cancer
138. Chromosomal changes during development and progression of prostate adenocarcinomas
139. DPC4 gene in various tumor types
140. High frequency of LOH at chromosome 18q in human breast cancer: Association with high S-phase fraction and low progesterone receptor content
141. Allelotyping of ductal carcinoma in situ of the breast: Deletion of loci on 8p, 13q, 16q, 17p and 17q
142. Molecular cytogenetics of primary breast cancer by CGH
143. Pattern of gene alterations in intraductal breast neoplasms associated with histological type and grade
144. Mapping of a breast cancer tumor suppressor gene locus to a 4-cM interval on chromosome 18q21
145. Prognostic significance of accumulation of gene and chromosome alterations and histological grade in node-negative breast carcinoma
146. Prognostic significance of allelic imbalance of chromosome arms 7q, 8p, 16q, and 18q in stage T3N0 MO prostate cancer
147. Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer
148. Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer
149. Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization
150. Expression of inhibin α, βA and βB messenger ribonucleic acids in the normal human ovary and in polycystic ovarian syndrome
151. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle
152. Immunohistochemical localization of inhibin/activin subunits in human ovarian follicles during the menstrual cycle
153. Serum inhibins A and B fall differentially as FSH rises in perimenopausal women
154. Inhibin and related peptides in the regulation of reproduction
155. Inhibin
156. The post-operative gonadotropin level in post-menopausal women with epithelial ovarian cancer
157. Characterization of inhibin immunoreactivity in post-menopausal women with ovarian tumours
158. Inhibin as a marker for ovarian cancer
159. Inhibin immunoreactivity in gonadal and non-gonadal tumors
160. Clinical and pathophysiological aspects of inhibin
161. A prospective study of inhibin in granulosa cell tumors of the ovary
162. Expression and secretion of inhibin and activin in normal and neoplastic uterine tissues: High levels of serum activin A in women with endometrial and cervical carcinoma
163. Immunoreactive inhibin, Mullerian inhibitory substance, and activin as biochemical markers for juvenile granulosa cell tumors
164. Peripheral vein, ovarian vein and ovarian tissue levels of inhibin in a postmenopausal patient with a granulosa cell tumour
165. Production of inhibin A and inhibin B in human ovarian sex cord stromal tumors
166. Characterization of an immortalized human granulosa cell line (COV434)
167. Inhibin forms in serum from postmenopausal women with ovarian cancers
168. α and β subunits of inhibin/activin as sex cord-stromal differentiation markers
169. Inhibin subunit gene expression in ovarian cancer
170. Immunohistochemical expression of inhibin/activin subunits in epithelial and granulosa cell tumors of the ovary
171. Immunoexpression of inhibin α subunit, inhibin/activin βA subunit and CD99 in ovarian tumors
172. Monoclonal antibodies against inhibin represent key markers of adult granulosa cell tumors of the ovary even in their metastases: A report of three cases with late metastasis, being previously misinterpreted as hemangiopericytoma
173. The site of inhibin production in ovarian neoplasms
174. Inhibin and activin are demonstrable by immunohistochemistry in ovarian tumor tissue
175. Value of inhibin in the identification of granulosa cell tumors of the ovary
176. Inhibin expression in ovarian tumors and tumor-like lesions: An immunohistochemical study
177. α-Inhibin immunostaining in diagnostic pathology
178. Immunohistochemical staining of normal, hyperplastic, and neoplastic adrenal cortex with a monoclonal antibody against α inhibin
179. The diagnostic utility of inhibin staining in ovarian neoplasms
180. Inhibin and epithelial membrane antigen immunohistochemistry assist in the diagnosis of sex cord-stromal tumors and provide clues to the histogenesis of hypercalcemic small cell carcinomas
181. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary
182. Diagnostic value of inhibin immunoreactivity in ovarian gonadal stromal tumors and their histological mimics
183. Mullerian inhibiting substance, α-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors
184. Transition from benign to malignant epithelium in mucinous and serous ovarian cystadenocarcinoma
185. Early de novo ovarian cancer and cancer developing in benign ovarian lesions
186. Benign ovarian cysts and ovarian cancer: A cohort study with implications for screening
187. Histologically benign or low-grade malignant tumors adjacent to high-grade ovarian carcinomas contain molecular characteristics of high-grade carcinomas
188. Immunohistochemical localization of inhibin and activin subunits in human epithelial ovarian tumors
189. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer
190. A comparative study of serum α-βA immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer
191. Secretion of activin A in recurrent epithelial ovarian carcinoma
192. Multiple immunoreactive inhibin proteins in serum from postmenopausal women with epithelial ovarian cancer
193. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: A study using inhibin and cytokeratin 7
194. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies
195. Inhibin B is the major form of inhibin/activin family secreted by granulosa cell tumors
196. Presence of activin, inhibin, and follistatin in epithelial ovarian carcinoma
197. Characterization of inhibin/activin subunit, follistatin, and activin type II receptors in human ovarian cancer cell lines: A potential role in autocrine growth regulation
198. Transformation of human granulosa cells with the E6 and E7 regions of human papillomavirus
199. Long-term growth and steroidogenic potential of human granulosa-lutein cells immortalized with SV40 large T antigen
200. Induction of Ad4BP/SF-1, steroidogenic acute regulatory protein, and cytochrome P450 scc enzyme system expression in newly established human granulosa cell lines
201. Establishment of steroidogenic granulosa cell lines expressing follicle stimulating hormone receptors
202. Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor
203. The regulation of apoptosis by activin and transforming growth factor-β in early neoplastic and tumorigenic ovarian surface epithelium
204. Studies on immunocytochemical localization of inhibin-like material in human prostatic tissue: Comparison of its distribution in normal, benign and malignant prostates
205. The amino acid sequence of human β-microseminoprotein
206. Prostatic specific antigen and immunoglobulin binding factor in human seminal plasma and prostate
207. Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as β-inhibin
208. Inhibin-related proteins in rat prostate
209. Expression and localization of inhibin/activin subunits and activin receptors in the normal rat prostate
210. Inhibins, activins, and follistatins: Expression of mRNAs and cellular localization in tissues from men with benign prostatic hyperplasia
211. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer
212. Activin inhibition of prostate cancer cell growth: Selective actions on androgen-responsive LNCaP cells
213. Growth inhibitory response to activin A and B by human prostate tumor cell lines, LNCaP and DU145
214. Prostate cancer in a transgenic mouse
215. Activin inhibits basal and androgen-stimulated proliferation and induces apoptosis in the human prostatic cancer cell line, LNCaP
216. Regulation of growth and prostatic marker expression by activin A in an androgen-sensitive prostate cancer cell line LNCAP
217. Identification of an activin-follistatin growth modulatory system in the human prostate: Secretion and biological activity in primary cultares of prostatic epithelial cells
218. The contribution of inhibins and activins to malignant prostate disease
219. Expression of activin A and follistatin core proteins by human prostate tumor cell lines
220. Measurement of inhibin concentrations in men: Study of changes after castration and comparison with androgen levels in testicular tissue, spermatic venous blood, and peripheral venous blood
221. Regulation of inhibin production in the human male and its clinical applications
222. The roles of inhibin and related peptides in gonadal function
223. Testicular activin - Too hot to handle?
224. Serum inhibin B levels reflect Sertoli cell function in normal men and men with testicular dysfunction
225. Serum inhibin levels in normal men and men with testicular disorders
226. Immunohistochemical localization of inhibin-α in the testes of normal men and in men with testicular disorders
227. Testicular expression of inhibin and activin subunits and follistatin in the rat and human fetus and neonate and during postnatal development in the rat
228. Inhibin B in seminal plasma: Testicular origin and relationship to spermatogenesis
229. Testicular Sertoli cell tumor with a heterologous sarcomatous component: Immunohistochemical assessment of Sertoli cell differentiation
230. Inhibin gene expression in a large cell calcifying Sertoli cell tumour and serum inhibin and activin levels
231. Inhibin, gonadotrophins and sex steroids in dogs with Sertoli cell tumors
232. Ageing, testicular tumors and the pituitary-testis axis in dogs
233. Undetectable inhibin B serum levels in men after testicular irradiation
234. Granulosa cell tumour of the testis displaying immunoreactivity for inhibin
235. Sex cord-stromal tumors of the testis with entrapped germ cells: A lesion mimicking unclassified mixed germ cell sex cord-stromal tumors
236. Circulating levels of inhibin in cancer
237. Human mammary gland and breast carcinoma contain immunoreactive inhibin/activin subunits: Evidence for a secretion into cystic fluid
238. Expression and localization of inhibin/activin subunits and activin receptors in MCF-7 cells, a human breast cancer cell line
239. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells
240. Resistance to transforming growth factor β and activin due to reduced receptor expression in human breast tumor cell lines
241. The expression of inhibin/activin subunits in the human adrenal cortex and its tumours
242. A comparison of A103 and inhibin reactivity in adrenal cortical tumors: Distinction from hepatocellular carcinoma and renal tumors
243. The α subunit of inhibin in adrenal cortical neoplasia
244. Anti-α-inhibin: Marker of choice for the consistent distinction between adrenocortical carcinoma and renal cell carcinoma in fine-needle aspiration
245. Inhibin, activin, and follistatin: Regulation of follicle-stimulating hormone messenger ribonucleic acid levels
246. Activin stabilizes follicle-stimulating hormone-β messenger ribonucleic acid levels
247. Inhibins, activins, follistatin, and GnRH: Regulators of gonadotropin subunit gene expression
248. Production and regulation of inhibin subunits in pituitary gonadotropes
249. The cytogenesis and pathogenesis of pituitary adenomas
250. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-β receptors in human pituitary adenomas
251. Decreased follistatin gene expression in gonadotroph adenomas
252. Activin effects on neoplastic proliferation of human pituitary tumors
253. Pituitary tumorigenesis and hPit-1 cells
254. Mutational analysis of activin/transforming growth factor-β type I and type II receptor kinases in human pituitary tumors
255. Genetic alterations of the transforming growth factor β receptor genes in pancreatic and biliary adenocarcinomas
256. Immunohistochemical localization of α- and βA-subunits of inhibin/activin in human normal endocrine cells and related tumors of the digestive system
257. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas
258. Ovarian-like stroma in an invasive mucinous cystadenocarcinoma of the pancreas positive for inhibin: A hint concerning its possible histogenesis
259. Mucinous cystic tumors of the pancreas: Clinicopathological features, prognosis, and relationship to other mucinous cystic tumors
260. Localization of the cellular expression of inhibin in trophoblastic tissue
261. Immunohistochemical localization of inhibin-activin subunits in hydatidiform mole and invasive mole
262. Localization, secretion, and action of inhibin in human placenta
263. Inhibin subunits in human placenta: Localization and messenger ribonucleic acid levels during pregnancy
264. Immunohistochemical localization of inhibin-α in the placenta and gestational trophoblastic lesions
265. Detection of the α-subunit of inhibin in trophoblastic neoplasia
266. Placental site nodule and characterization of distinctive types of intermediate trophoblast
267. Serum levels of dimeric activin A are not a marker of placental tumors in the course of chemotherapy
268. Inhibin and activin subunits are differentially expressed in endometrial cells and leukocytes during the menstrual cycle, in early pregnancy and in women using progestin-only contraception
269. The existence of activin A/erythroid differentiation factor and its inhibitor in human serum: Comparison of normal and chronic renal failure sera
270. Determination of free follistatin levels in sera of normal subjects and patients with various diseases
271. Inhibin is not an immunohistochemical marker for hepatocellular carcinoma. An example of the potential pitfall in diagnostic immunohistochemistry caused by endogenous biotin
272. Immunohistochemical staining of hepatocellular carcinoma with monoclonal antibody against inhibin
273. Adult granulosa cell tumor of the ovary with foci of hepatic cell differentiation: A report of four cases and comparison with two cases of granulosa cell tumor with Leydig cells
274. Hepatocytic differentiation in retiform Sertoli-Leydig cell tumors: Distinguishing a heterologous element from Leydig cells
275. Interruption of activin A autocrine regulation by antisense oligodeoxynucleotides accelerates liver tumor cell proliferation
276. Activin A regulates growth and acute phase proteins in the human liver cell line, HepG2
277. Activin induces cell death in hepatocytes in vivo and in vitro
278. Identification and analysis of tumor suppressor genes using transgenic mouse models
279. Differential response to exogenous and endogenous activin in a human ovarian teratocarcinoma-derived cell line (PA-1): Regulation by cell surface follistatin